FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2506561330> ?p ?o ?g. }

• W2506561330 endingPage "56797" @default.
• W2506561330 startingPage "56781" @default.
• W2506561330 abstract "// Oliver Wood 1, * , Jeongmin Woo 1, * , Gregory Seumois 3, * , Natalia Savelyeva 1 , Katy J. McCann 1 , Divya Singh 3 , Terry Jones 2 , Lailah Peel 1 , Michael S. Breen 1 , Matthew Ward 1 , Eva Garrido Martin 1 , Tilman Sanchez-Elsner 1, # , Gareth Thomas 1, # , Pandurangan Vijayanand 1, 3, # , Christopher H. Woelk 1, # , Emma King 1, # , Christian Ottensmeier 1, # , for the SPARC Consortium 1 Faculty of Medicine, University of Southampton & University Hospital Southampton, Southampton, UK 2 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK 3 La Jolla Institute for Allergy & Immunology, La Jolla, CA, USA * These first authors have contributed equally to this work # These senior authors have contributed equally to this work Correspondence to: Emma King, email: e.king@soton.ac.uk Christopher H. Woelk, email: C.H.Woelk@soton.ac.uk Keywords: head and neck squamous cell carcinoma, human papilloma virus, tumor-infiltrating lymphocyte, RNA-Sequencing, transcriptome Received: February 15, 2016     Accepted: June 30, 2016     Published: July 22, 2016 ABSTRACT Human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) has a better prognosis than it’s HPV negative (HPV(−)) counterpart. This may be due to the higher numbers of tumor-infiltrating lymphocytes (TILs) in HPV positive (HPV(+)) tumors. RNA-Sequencing (RNA-Seq) was used to evaluate whether the differences in clinical behaviour simply reflect a numerical difference in TILs or whether there is a fundamental behavioural difference between TILs in these two settings. Thirty-nine HNSCC tumors were scored for TIL density by immunohistochemistry. After the removal of 16 TIL low tumors, RNA-Seq analysis was performed on 23 TIL high/med tumors (HPV(+) n=10 and HPV(−) n=13). Using EdgeR, differentially expressed genes (DEG) were identified. Immune subset analysis was performed using Functional Analysis of Individual RNA-Seq/ Microarray Expression (FAIME) and immune gene RNA transcript count analysis. In total, 1,634 DEGs were identified, with a dominant immune signature observed in HPV(+) tumors. After normalizing the expression profiles to account for differences in B- and T-cell number, 437 significantly DEGs remained. A B-cell associated signature distinguished HPV(+) from HPV(−) tumors, and included the DEGs CD200, GGA2, ADAM28, STAG3, SPIB, VCAM1, BCL2 and ICOSLG ; the immune signal relative to T-cells was qualitatively similar between TILs of both tumor cohorts. Our findings were validated and confirmed in two independent cohorts using TCGA data and tumor-infiltrating B-cells from additional HPV(+) HNSCC patients. A B-cell associated signal segregated tumors relative to HPV status. Our data suggests that the role of B-cells in the adaptive immune response to HPV(+) HNSCC requires re-assessment." @default.
• W2506561330 created "2016-08-23" @default.
• W2506561330 creator A5006061539 @default.
• W2506561330 creator A5012587144 @default.
• W2506561330 creator A5015610349 @default.
• W2506561330 creator A5017045621 @default.
• W2506561330 creator A5020989903 @default.
• W2506561330 creator A5026388425 @default.
• W2506561330 creator A5026627346 @default.
• W2506561330 creator A5035221639 @default.
• W2506561330 creator A5039035938 @default.
• W2506561330 creator A5050904472 @default.
• W2506561330 creator A5057494435 @default.
• W2506561330 creator A5063219325 @default.
• W2506561330 creator A5066979997 @default.
• W2506561330 creator A5072238075 @default.
• W2506561330 creator A5082688752 @default.
• W2506561330 creator A5085481160 @default.
• W2506561330 creator A5085572260 @default.
• W2506561330 date "2016-07-22" @default.
• W2506561330 modified "2023-10-12" @default.
• W2506561330 title "Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors" @default.
• W2506561330 cites W137881775 @default.
• W2506561330 cites W148731515 @default.
• W2506561330 cites W1530897177 @default.
• W2506561330 cites W1981178993 @default.
• W2506561330 cites W1983395516 @default.
• W2506561330 cites W1986241711 @default.
• W2506561330 cites W1986311875 @default.
• W2506561330 cites W1989532420 @default.
• W2506561330 cites W1991724442 @default.
• W2506561330 cites W1995334682 @default.
• W2506561330 cites W2005735929 @default.
• W2506561330 cites W2015657357 @default.
• W2506561330 cites W2016967137 @default.
• W2506561330 cites W2017138237 @default.
• W2506561330 cites W2018641619 @default.
• W2506561330 cites W2020830322 @default.
• W2506561330 cites W2028433016 @default.
• W2506561330 cites W2041557663 @default.
• W2506561330 cites W2051587095 @default.
• W2506561330 cites W2051878844 @default.
• W2506561330 cites W2056933088 @default.
• W2506561330 cites W2061572018 @default.
• W2506561330 cites W2062312459 @default.
• W2506561330 cites W2069896987 @default.
• W2506561330 cites W2069906370 @default.
• W2506561330 cites W2077909276 @default.
• W2506561330 cites W2091777938 @default.
• W2506561330 cites W2099443640 @default.
• W2506561330 cites W2107277218 @default.
• W2506561330 cites W2107531479 @default.
• W2506561330 cites W2107894271 @default.
• W2506561330 cites W2108836663 @default.
• W2506561330 cites W2110664940 @default.
• W2506561330 cites W2114104545 @default.
• W2506561330 cites W2116830437 @default.
• W2506561330 cites W2123130879 @default.
• W2506561330 cites W2129271267 @default.
• W2506561330 cites W2132239791 @default.
• W2506561330 cites W2134410087 @default.
• W2506561330 cites W2134526812 @default.
• W2506561330 cites W2135398071 @default.
• W2506561330 cites W2139376220 @default.
• W2506561330 cites W2141024484 @default.
• W2506561330 cites W2142300779 @default.
• W2506561330 cites W2143680521 @default.
• W2506561330 cites W2144642115 @default.
• W2506561330 cites W2148028028 @default.
• W2506561330 cites W2153578144 @default.
• W2506561330 cites W2157041114 @default.
• W2506561330 cites W2162833793 @default.
• W2506561330 cites W2168420558 @default.
• W2506561330 cites W2192080449 @default.
• W2506561330 cites W2525708006 @default.
• W2506561330 cites W43732924 @default.
• W2506561330 doi "https://doi.org/10.18632/oncotarget.10788" @default.
• W2506561330 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5302866" @default.
• W2506561330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27462861" @default.
• W2506561330 hasPublicationYear "2016" @default.
• W2506561330 type Work @default.
• W2506561330 sameAs 2506561330 @default.
• W2506561330 citedByCount "82" @default.
• W2506561330 countsByYear W25065613302016 @default.
• W2506561330 countsByYear W25065613302017 @default.
• W2506561330 countsByYear W25065613302018 @default.
• W2506561330 countsByYear W25065613302019 @default.
• W2506561330 countsByYear W25065613302020 @default.
• W2506561330 countsByYear W25065613302021 @default.
• W2506561330 countsByYear W25065613302022 @default.
• W2506561330 countsByYear W25065613302023 @default.
• W2506561330 crossrefType "journal-article" @default.
• W2506561330 hasAuthorship W2506561330A5006061539 @default.
• W2506561330 hasAuthorship W2506561330A5012587144 @default.
• W2506561330 hasAuthorship W2506561330A5015610349 @default.
• W2506561330 hasAuthorship W2506561330A5017045621 @default.
• W2506561330 hasAuthorship W2506561330A5020989903 @default.
• W2506561330 hasAuthorship W2506561330A5026388425 @default.

• next